Floatz logo

Therapeutic Asset Ratings

409 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
uv1
Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials UnitP2CC (46)
Valemetostat
Ovarian Cancer
Gustave Roussy, Cancer Campus, Grand ParisP2CC (46)
Vesanoid
Ovarian Cancer
Peking University People's HospitalP2CC (46)
Volrustomig
Ovarian Cancer
AstraZenecaP2CC (46)
Yangzheng Xiaoji
Ovarian Cancer
Sichuan Cancer Hospital and Research InstituteP2CC (46)
Zanidatamab
Ovarian Cancer
Jazz PharmaceuticalsP2CC (46)
Zeprumetostat
Ovarian Cancer
Peking University Third HospitalP2CC (46)
αdc1 vaccine
Ovarian Cancer
Kalinski, Pawel, MD, PhDP2CC (46)
Nelfinavir
Ovarian Cancer
Medical University of South CarolinaP2CC (45)
Rintatolimod
Ovarian Cancer
Kalinski, Pawel, MD, PhDP2CC (45)
Theo-260
Ovarian Cancer
Theolytics LimitedP1/2CC (45)
Nirogacestat
Ovarian Cancer
SpringWorks Therapeutics, Inc.P2CC (44)
Polyiclc
Ovarian Cancer
Dana-Farber Cancer InstituteP1/2CC (44)
Copanlisib
Ovarian Cancer
M.D. Anderson Cancer CenterP2CC (43)
n-803
Ovarian Cancer
ImmunityBio, Inc.P2CC (43)
Sotigalimab
Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials UnitP2CC (43)
sl-172154
Ovarian Cancer
Shattuck Labs, Inc.P1CC (42)
e-602
Ovarian Cancer
Palleon Pharmaceuticals, Inc.P1/2CC (42)
H-gamma1 heavy chain Homo sapiens (1-447) [VH (Homo sapiens IGHV4-59*01 (99.0%) -(IGHD) -IGHJ3*02 (93.3%) T125>I (114), CDR-IMGT [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 9-G1v21 CH2 Y15.1, T16, E18 (CH1 K120 (214) (118-215), hinge 1-15 (216-230), CH2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), CH3 D12 (356), L14 (358) (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-11*01 (96.8%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (CKAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide, produced in a cell line derived from Chinese hamster ovary (CHO) cells, glycoform alfa
Ovarian Cancer
Kineta Inc.P1/2CC (42)
il15-transpresenting wt1-targeted dendritic cell vaccine
Ovarian Cancer
University Hospital, AntwerpP1/2CC (42)
Vudalimab
Ovarian Cancer
Xencor, Inc.P2CC (40)
[111in]-fpi-1967
Ovarian Cancer
Fusion Pharmaceuticals Inc.P1/2CC (40)
177lu-betabart
Ovarian Cancer
Radiopharm Theranostics, LtdP1/2CC (40)
[203pb]pb-psv359
Ovarian Cancer
Perspective TherapeuticsP1/2CC (40)
[212pb]pb-psv359
Ovarian Cancer
Perspective TherapeuticsP1/2CC (40)
Showing 176 to 200 of 409 assets
PreviousPage 8 of 17Next